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ABSTRACT
Drug use is a public health issue with one-third of the United States population
having reported consuming marijuana at some point in their lifetime. This paper
examines how the perception of risk (both health and criminal sanctions) affects
consumption behavior. This study examined marijuana consumption for the age ranges of
12-17, 18-25, and 26 and older during the years of 1999-2007.
Perceptions of health risk of marijuana vary from by age groups (12-17, 18-25,
and 26 years of age and up). Persons age 26 and older perceive the health risks to be the
greatest for occasional marijuana consumption, trailed by youth age 12-17, and 18-25
with the lowest perception of health risk. Residing in a medical marijuana state was the
strongest single predictor of past month marijuana use. Marijuana possession criminal
classification for marijuana possession was the second strongest influencer, marijuana
health risk perception was third strongest, residing in a marijuana decriminalized state is
fourth, and marijuana price per gram was fifth strongest respectively. Possible maximum
monetary fine for marijuana possession was the weakest influencer on past month
marijuana consumption with almost zero influence.
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CHAPTER I
INTRODUCTION

Drug use is a major public health issue in the United States (Winters, 2003).
Marijuana is the most commonly used illicit drug in the developed world, with one-third
of the population in both Australia and the United States have reported consuming
marijuana at some point in their lifetime (Williams, 2004). In 2010 U.S. residents spent
between $30 billion and $60 billion on marijuana ("What America's Users Spend on
Illegal Drugs: 2000-2010," 2014).
The purpose of this paper is to attempt to identify how the perception of risk (both
health and criminal sanctions) affects marijuana consumption. This study examined
marijuana consumption for the age ranges of 12-17, 18-25, and 26 and older during the
years of 1999-2007, and how the perception of risk influenced consumption patterns.
Increasing prevalence of regular cannabis use, as well as new epidemiological
research on the hazards of marijuana consumption, are prompting policy makers to view
cannabis as a potential serious health risk (Hall & Babor, 2000). Since the 1970s, the
proportion of young people who have used cannabis has dramatically increased while the
age of first use has declined (Hall, 2006) and more adults in the United States had a
marijuana disorder in 2001-2002 than in 1991-1992 (Compton, Grant, Colliver, Glantz,
& Stinson, 2004). The actual prevalence of marijuana smoking is likely higher than is
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reported due to the fact that national surveys under-represent high school dropouts and
those whose drug use is higher than the surveyed population (Tashkin, 1993).
Marijuana smoke contains significantly more carcinogens (Marselos &
Karamanakos, 1999; Zhang et al., 1999) and deliver more tar to the lungs than tobacco
smoke (Mehra, Moore, Crothers, Tetrault, & Fiellin, 2006). When consuming marijuana
larger puff volumes are taken and the smoke from marijuana is inhaled more deeply. This
results in the individual retaining smoke in his or her lungs, approximately four times
longer than tobacco smoke, and a larger amount of tar retained in the lung (Mehra et al.,
2006; Sherman, Roth, Gong Jr., & Tashkin, 1991).
Biological evidence does support a correlation between marijuana smoking and
the development of lung cancer in humans (Mehra et al., 2006). Strong evidence does
exist that demonstrates that cannabis smoke produces mutations in cells in both test tubes
and within live animals and therefore can be a potential cause of cancer (Hall,
Degenhardt, & Lynskey, 2001). Taylor reviewed surgical pathology reports of patients
under the age of 40 who had been diagnosed with respiratory tract carcinoma (a
malignant tumor). Marijuana use of these patients was then examined, and the author
concluded that regular marijuana use adds significant risk for the development of
respiratory tract carcinoma (F. M. Taylor, 1988).
A study conducted between 1992 and 1994 examined the relationship between
marijuana consumption and cancer of the head and neck. Patients with cases of confirmed
squamous cell carcinoma (skin cancer), along with a control group of cancer-free persons
completed questionnaires concerning tobacco, alcohol, and marijuana use. The authors
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concluded that marijuana use may increase the risk of head and neck cancer (Zhang et al.,
1999).
Exposing a correlation between marijuana smoking and various forms of cancer is
complicated due to the fact that many marijuana users also exposed themselves to
additional risk factors such as tobacco and alcohol consumption. However, Caplan and
Brigham reported two cases of marijuana smoking and carcinoma of the tongue in which
both males (age 37 and 52) denied any tobacco or alcohol consumption but reported
heavy marijuana use (Caplan & Brigham, 1990). Almadori at al. described a case of a 23year-old male suffering from cancer of the tongue. This case was unusual due to the fact
that persons under the age of 30 are diagnosed with this form of cancer in only
approximately 3% of cases of head and neck cancers (Randall & Shaw, 1986). This
patient smoked cigarettes and was also a self-reported  “regular”  marijuana  smoker.  This  
study concluded that the addition of marijuana may have contributed to his condition due
to the young age of the patient and the relatively short period of being a cigarette smoker
(Almadori, Paludetti, Cerullo, Ottaviani, & D'Alatri, 1990).
One study demonstrated an association between marijuana use and the incidence
of testicular germ cell tumors (TGCT) (Daling et al., 2009). This study, consisting of
1,348 males (369 with TGCT and 979 without) age 18-44, stated that marijuana use
produces adverse effects on the human endocrine and reproductive systems that resulted
in a 70 % increased risk of TGCT. This health risk was elevated for weekly, or greater,
current marijuana use or marijuana use that began in adolescence.
A 1997 published study demonstrated that among non-tobacco smoking persons,
marijuana use was linked to an increased risk of prostate cancer (Sidney, Quesenberry,
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Friedman, & Tekawa, 1997). This study, conducted between the years of 1979 and 1985,
examined 64,855 patients of Kaiser Permanente in San Francisco and Oakland,
California. Self-administered questionnaires measured smoking habits of both marijuana
and tobacco. A follow-up examination of incidence of cancer was also conducted in
1993, which resulted in the researchers concluding that marijuana use by non-cigarette
smokers  may  have  an  increased  risk  for  some  “site-specific”  cancer  risks (Sidney et al.,
1997). Although this study does possess some limitations, it does raise questions of
potential hormonal alterations due to marijuana consumption (Sidney et al., 1997).
Marijuana use has also been shown to negatively affect the female reproductive
system by suppressing the plasma levels of luteinizing hormone during the luteal phase of
the menstrual cycle, shortened luteal phase and overall cycle length and anovulation
(Holt, Cushing-Haugen, & Daling, 2005). Holt et al. also concluded that an increased risk
of ovarian cyst cancer exists for underweight and normal-weight females who use
marijuana. Marijuana use among non-tobacco using females is also associated with an
increased risk of cervical cancer (Sidney et al., 1997).
Several studies have been conducted to determine the correlation between
marijuana consumption and negative mental health conditions. One longitudinal study
utilizing data gathered from the Netherlands Mental Health Survey and Incidence Study,
in which subjects were contacted once during the years 1996, 1997 and 1999, concerned
the prevalence, incidence, course, and consequences of psychiatric disorders (van Os et
al., 2002). The initial numbers of subjects contacted in 1996 was 7,076, with that number
dropping to 5,618 in 1997, and 4,848 in 1999. This study concluded that psychosis-free
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subjects who have a lifetime history of cannabis use are at increased risk of a psychosis
outcome (van Os et al., 2002).
A 2007 meta-analysis further demonstrated the relationship between cannabis use
and the risk of future onset of psychosis. The authors concluded that the risk of psychosis
increased by approximately 40% by persons who have used cannabis, and that there is
dose-response effect leading to an increased risk of 50-200% in the most frequent users
(Nordentoft & Hjorthoj, 2007). Findings such as this can have a tremendous effect on
influencing future health outcomes. For example, assuming an increased risk of psychosis
of 40 % and a 40 % lifetime cannabis use among young adults in the UK, then one could
expect a 14% reduction in psychotic outcomes if cannabis was not used in that society
(Nordentoft & Hjorthoj, 2007).
Cannabis use has been associated with both positive and negative dimensions of
psychosis, independent of each other, and depression (Stefanis et al., 2004). Furthermore,
research on brain development clearly demonstrates that the adolescent brain, which is
still developing, is particularly vulnerable to the ill effects of substance abuse, including
marijuana (Joffe, 2005). These findings were similar to a previous analysis conducted by
Arseneault et al., who concluded that heavy cannabis use at the age of 18 increased the
risk of later schizophrenia six-fold (Arseneault et al., 2002). Cannabis use may trigger
schizophrenia in persons who are vulnerable to the disorder; cannabis may also be used to
“self-medicate”  schizophrenia  symptoms  (Hall, 2006). The difficulty lies in deciphering
the degree of correlation and the assumptions surrounding persons who may be
predisposed of certain behaviors.
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Marijuana intoxication has also been implicated as a risk factor for injuries
(Polen, Sidney, Tekawa, Sadler, & Friedman, 1993). Chronic marijuana users have also
been shown to have impairments in attention, memory, and the ability to process complex
information for months or even years after ceasing marijuana consumption (Ashton,
2001).
In addition to health-related issues, marijuana consumption places tremendous
costs onto society. One 1992 study quantifies the social cost of marijuana at $7.2 billion,
or 8.9% of drug-related social costs, such as increased healthcare, loss of productivity,
and lower educational level of attainment (Caulkins, Pacula, Paddock, & Chiesa, 2002).
The authors admittedly concede that this measure is less precise than that of other drugrelated  social  costs  due  to  marijuana  “rarely  being  the  sole  or  principal  cause  of  
measurable  harms  such  as  an  overdose.”  Additional  estimates  argue  that  the social value
of averting or delaying each case of schizophrenia is approximately $500,000, which
greatly exceeds the per-patient lifetime cost-of-illness estimates for psychotic disorders
(Pollack & Reuter, 2007). Pollack and Reuter further argue that a 20% reduction in
marijuana use would be associated with a $600 million savings in averted social costs.
Additional social costs result from marijuana use hindering personal achievement,
such as graduating from high school. Failure to graduate from high school can be related
to a lack of occupational opportunities, lower lifetime earnings, reduced community
involvement, and lower self-esteem. High school graduation is negatively associated with
marijuana use. More specifically a 10% increase in frequent marijuana use lowers the
probability of graduation by 6.62% (Yamada, Kendix, & Yamada, 1996). Other
researchers have further investigated this hypothesis. Studies have demonstrated a
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correlation between marijuana consumption and low grade point averages, decreased
attendance, and an increased drop-out rate. A study published in 1996 of 1,000 youths
concluded that 22.5% of youths who self-reported cannabis use before the age of 15 had
dropped out of school by the age of 16 (Lynskey & Hall, 2000).
Fergusson and Horwood conducted a longitudinal cohort study of youths born in
Christchurch, New Zealand in 1977. The youths were studied at birth, 4 months, 1 year,
annually through age 16, and finally at age 18. Early onset marijuana users had
significantly higher rates of later substance use, juvenile offending, mental health
problems, unemployment, and dropping out of school (Fergusson & Horwood, 1997).
Youths aged 15-16 years old who consumed marijuana on more than 10 occasions are
almost four times more likely to drop out of school than a youth the same age who had
never consumed marijuana, and almost ten times more likely to have attempted suicide
(Fergusson & Horwood, 1997).
Cannabis is an addictive substance and the addiction can result from
experimentation and recreational use (van den Brink, 2008). Marijuana dependence is
defined in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) as
increased tolerance, compulsive use, impaired control, and continued use despite physical
and psychological problems caused or exacerbated by use (Diagnostic and statistical
manual of mental disorders, 2000). Marijuana is much more potent now than it was in the
1960s and 1970s, which is one explanation why cannabis-use disorders in the United
States have increased over the past 10 years (Joffe, 2005). Surveys in both the United
States and Australia show that cannabis dependence is the most common form of
dependence after alcohol and tobacco (Hall et al., 2001).
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A growing body of research has examined the relationship between the genetic
epidemiology of addiction. Approximately 10% of marijuana users become dependent on
the drug (Anthony, Warner, & Kessler, 1994). In 2011 approximately 4.2 million persons
met the American Psychiatric Association’s  Diagnostic  and  Statistical  Manual  of  Mental  
Disorders (DSM-IV) diagnostic criteria for marijuana use or dependence ("Substance
Abuse and Mental Health Services Administration," 2012). It has been suggested that
marijuana use, abuse, and dependence tend to aggregate in families (Agrawal & Lynskey,
2006). The risk of marijuana dependence is higher for daily users and persons who begin
consuming marijuana at an early age (Coffey, Carlin, Lynskey, Li, & Patton, 2003).
Additional health concerns are raised due to the increased potency of marijuana
consumed today versus the past. Consumption patterns may be negatively affected by this
increase of potency. As the potency of marijuana increases the amount consumed may
decrease if users adjust to keep the amount of THC per day of use stable ("What
America's Users Spend on Illegal Drugs: 2000-2010," 2014). Consumption of marijuana
may be characterized by reinforcement (greater past consumption increases the desire for
present consumption), tolerance (utility of a given consumption level is lower when past
consumption is higher), and withdrawal symptoms (fall in utility from abrupt cessation in
consumption pattern) (Bretteville-Jensen, 2006). This dependence can lead to serious
withdrawal symptoms once the stimulant is removed.
Withdrawal symptoms have been reported by 80% of male and 60% of female
adolescents seeking treatment for cannabis dependence (Hall, 2006). These withdrawal
symptoms are similar to those of alcohol, opiates, and benzodiazepine withdrawal, which
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includes restlessness, insomnia, anxiety, increased aggression, and muscle tremors
(Ashton, 2001).
The risk of death from marijuana overdose is incredibly low. There are no
reported cases of human deaths attributed to cannabis toxicity (Hall et al., 2001). That is
not to say that cannabis toxicity is not possible: it is just extremely unlikely that a person
can  consume  the  quantity  needed  to  cause  death.  On  average,  one  “joint”  delivers  3  mg  of  
THC to the consumer while the lethal dose is approximately 4,000 mg of THC (Gable,
1993) or  more  than  1,300  “joints.”

Marijuana Regulation
Opponents of marijuana prohibition argue that the legalization of marijuana will
allow the market to operate in the most efficient manner. Drugs such as marijuana,
cocaine, and heroin have not created any market failures that justify an outright ban of
these substances, and our present drug policy has led to an increase in crime, social
disruption, and decreased respect for law enforcement (Block, 1993). Additional points of
view stem from the philosophical perspective, arguing that drug prohibition severely
threatens our civil liberties and is inconsistent with the anti-slavery philosophy and the
founding documents of the United States (Cussen & Block, 2000). This stance posits that
allowing for the free trade of marijuana will lead to an outcry from those who oppose
consumption of such a good, but other legal products produce similar reactions, such as
products tested on animals.
Adding to this stance is the viewpoint that legalizing and taxing marijuana in the
same way as other goods will generate a tremendous amount of revenue for federal, state,
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and local governments. The exact amount of the tax and amount generated is purely
speculative at this point in time. Finding an optimal tax rate is a complex and daunting
proposition. An optimal tax rate may exist that maximizes revenues and minimizes crime,
addiction, and youth consumption but the history with alcohol has demonstrated the
difficulty in finding the most efficient and effective tax rate (Wilson, 1990).
Drug policies are costly ones, but the exact costs are unclear. Rigter (2006)
analyzed the costs of drug policies in the Netherlands for four distinct areas (prevention,
treatment, harm reduction, and enforcement) for the 2003 calendar year. Although the
Netherlands  is  “soft”  on  personal  marijuana  possession  and  consumption,  they  allocate a
tremendous amount of capital to drug policies. For example, in 2003 the Dutch
government spent approximately €41.5 million ($52.2 million USD) on prevention alone,
with 25% of that amount devoted to school drug prevention programs and advertising
campaigns (Rigter, 2006). Law enforcement is the largest expenditure of the four
components of the Dutch drug policy. Enforcement expenditures in 2003 totaled €1.65
billion ($2.1 billion USD), €277.6 million ($349 million USD) for treatment, and €220
million ($276.8 million USD) on harm reduction (Rigter, 2006).
This distribution of resources is similar to the drug policy spending in Sweden.
Although Sweden spends far less in total Euros than does the Netherlands, their
percentage spending of the total budget is comparable. Both countries allocated 76% of
their drug control budget to enforcement in 2002-03, with Sweden outspending the
Netherlands in the area of treatment 19% to 13% respectively, and the Netherlands
outpacing Sweden in spending for both prevention (2% to 1%) and harm reduction (9%
to 0.1%) (Reuter, 2006).
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The United States has been publishing such data for approximately 35 years,
although this collection of data does not include the expenditures of state and local
governments (Carnevale & Murphy, 1999). From 1970-76, the majority of spending was
focused on reducing the demand-side of the drug problem. This spending shifted in 1977,
when spending shifted to reducing the supply of illegal drugs (Carnevale & Murphy,
1999). In 2011 the U.S. spent approximately $15.5 billion on the War on Drugs, or just
less then $500 per second (ONDCP, 2010)
Marijuana legalization in the United States would reduce government yearly
enforcement expenditures by approximately $7.7 billion while simultaneously generating
a tax revenue of $6.2 billion if marijuana was taxed at rates similar to alcohol and
tobacco or $2.4 billion if taxed like other goods (Miron, 2005), resulting in a potential
$14 billion that could be allocated to other budget items. Of that $7.7 billion, more than
$5 billion of the cost is incurred by state and local governments (Miron, 2005). In 2004
alone the State of Alaska directly spent approximately $16 million for marijuana
prohibition, including law enforcement and adjudication by the courts, and an additional
$8 million on indirect costs such as lost output and negative impacts on family (Bates,
2004).
Although marijuana is illegal on the federal level, some states have
decriminalized possession and cultivation for personal and/or medical purposes. The
National Commission on Marijuana and Drug Abuse defined decriminalization as those
policies in which possession of marijuana for personal use or casual distribution of small
amounts not intended to generate profits was not considered a criminal offense
("Marihuana: A signal of misunderstanding," 1972). This decriminalization has led to a
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decrease in the costs of consuming marijuana. As the costs of consumption fall,
marijuana use can be expected to increase. However, results from various studies have
done little to produce a consensus.

Legal Considerations
Potential negative effects of marijuana legalization include further harm to lowincome urban areas. These urban areas bear a disproportionate share of social costs of the
illegal drug trade, while also possibly receiving a disproportionate share of the economic
gain associated with illegal drug sales (Warner, 1991). This may be caused by the
elimination of the black market drug trade, thusly further eliminating a means of
economic gain for persons in this poor urban area, while other more affluent areas will
not be affected as much.
Decriminalization is not the same as legalization. Under a system of
decriminalization, marijuana is still technically illegal. Laws remain on the books;
however, law enforcement and other authorities at the federal, state, or local level simply
choose not to enforce many marijuana laws. Decriminalization models are most often
applied to areas where users primarily possess and consume small amounts of marijuana.
These individuals would no longer face the threat of a custodial arrest for such actions. In
1973, Oregon was the first state to decriminalize marijuana; followed by Colorado,
Alaska, and Ohio in 1975; California, Maine, and Minnesota in 1976; Mississippi, New
York, and North Carolina in 1977; and Nebraska in 1978 (MacCoun & Reuter, 2001).
Local-level examples of pre- and post-tests have been used to study of the effects
of marijuana decriminalization. In November of 1975, Ohio effectively decriminalized
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marijuana. Surveys conducted of persons aged 18-24 revealed that marijuana use among
that group increased from 6% from 1974 to 19% in 1978 (Single, 1989). California also
collected data appropriate to analyze their policy change. From February 1975 to
November 1976 the number of adults reporting that they had ever used marijuana
increased from 28% to 35% (Single, 1989).
Additional research in this area suggests that decriminalization or legalization of
marijuana, which will lead to a reduction of the full price of marijuana, would almost
certainly lead to an increase in marijuana consumption (Chaloupka & Laixuthai, 1997).
This study by Chaloupka and Laixuthai, consisting of data collected from the 1982 and
1989 Monitoring the Future surveys of high school seniors, also demonstrated that
lowering the price of marijuana, by either lower monetary prices and/or reduced legal
sanctions, would lead youths to substitute marijuana for higher priced alternatives such as
alcoholic beverages and other intoxicants, indicating that these substances are economic
substitutes.
However, results from studies concerning the end result of marijuana
decriminalization in the U.S. vary. Williams found that decriminalization does not in fact
appear to increase the likelihood of marijuana use among young males and females
(Williams, 2004). Williams argued that marijuana decriminalization is correlated to an
increased possibility of use in males over the age of 25 but not for younger persons,
concluding that the monetary cost of marijuana does play a role in consumption levels for
younger people who are more price sensitive than older groups. A separate study
concluded that decriminalization increases the probability of smoking marijuana by
16.2% (Damrongplasit, Hsiao, & Zhao, 2010). Pacula, Chriqui, and King concluded that
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youths residing in a state that has decriminalized marijuana are 2% more likely to use that
drug in both the past year and the past month (Pacula, Chriqui, & King, 2003).
A study of first-year students enrolled at the University of Western Australia
concluded that legalizing marijuana would lead consumption to increase by
approximately 4% with marijuana prices remaining at current levels, however,
legalization coupled with a 50% price decrease of marijuana would lead consumption to
increase by approximately 11% (Daryal, 1999). This study also concluded that persons
who are more frequent users of marijuana are more price responsive than those who
consume marijuana on a less frequent basis. A 2005 study of Australian youth also drew
interesting conclusions concerning price and consumption. Researchers demonstrated that
low marijuana prices are correlated with early initiation of marijuana use and a longer
duration of use (van Ours & Williams, 2007).

Criminal Penalties
Although the number of persons arrested for marijuana possession has increased
in absolute numbers, the percentage of arrests has remained steady. Regional variations in
arrests exist. Driven largely by police department policies and specific initiatives,
considerable discrepancies in marijuana arrest rates throughout the country exist. For
example in the 1990s New York City implemented a program to increase arrests for
persons using marijuana in public view. This initiative was a subset of quality-of-life
policing which was intended to promote public order in public locations by aggressively
targeting persons who engage in activities that offend the general public (Golub, Johnson,
& Dunlap, 2006). In 2000, 15% of all arrests by the New York City Police Department
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were for marijuana in public view violations, most of which were located in high poverty
and minority communities (Golub et al., 2006).
Some communities focus on drug enforcement for reasons other than quality-oflife benefits. Mast et al. demonstrated that in communities where state or local legislation
allows for police departments to retain a portion of assets seized during drug arrest the
percentage of drug arrests increase by approximately 18% (Mast, Benson, & Rasmussen,
2000). This study implies that police departments will allocate more resources to drug
enforcement  when  they  are  able  to  increase  their  departments’  budgets  through  asset  
seizures than when these financial incentives are not present.
In 2010, 13,120,947 persons were arrested (excluding traffic violations) in the
United States ("Crime in the United States," 2011). Of the persons arrested 1,643,846
person were arrested for drug abuse violations. Of this 1.6 million, just under 45.8% was
for marijuana possession, accounting for 12.5% of the total arrests for the year 2010 in
the U.S. The percentage of arrests for marijuana possession as a proportion of all illegal
drug arrests declined from the 1970s through the 1990s. In 1978, approximately 60% of
the arrests for illegal possession were related to marijuana, falling to approximately 35%
in 1996 (Ostrom & Kauder, 1999). During this time law enforcement shifted priorities
from marijuana to other drugs such as crack cocaine, which was labeled an epidemic
beginning in the 1980s.
In 2000 approximately 734,000 persons were arrested for marijuana-related
offenses, which resulted in only 41,000 felony convictions, producing only one felony
conviction for every eighteen persons arrested (King & Mauer, 2006). Marijuana dealers
carry less risk than heroin dealers; the average heroin dealer can expect to spend
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approximately 35% of his/her dealing career incarcerated while marijuana dealers only
spend 1% of their tenure incarcerated (Reuter & Kleiman, 1986).
Previous research has demonstrated that punitive sanctions have little influence on
marijuana usage, and monetary penalties possess little threat to users. One explanation is
that the general public does not know the level of monetary fines that a conviction for
marijuana possession carries. Individuals are generally poor judges of the certainty and
severity of criminal sanctions (Apel, 2013). Approximately one-third of households do
not know what the maximum penalty for marijuana possession is in their state (Pacula,
Kilmer, Grossman, & Chaloupka, 2007a). These findings suggest that changes in
monetary penalties will have little effect due to the nonexistent dissemination of this
information  to  the  states’  residents.  
Reduced jail time and lower sanctions are correlated with greater marijuana use;
however, this increase is relatively small and removing these penalties has little effect on
consumption (Pacula, Kilmer, Grossman, & Chaloupka, 2007b). People are not oblivious
to marijuana laws, their knowledge of the facts are shaky at best, and their recollection of
penalties revolves around information garnered through the policy debate of alternatives
and not the actual implementation (MacCoun, Pacula, Chriqui, Harris, & Reuter, 2008).
This suggests that deterring marijuana consumption through increasing price rather than
criminal sanctions may offer substantial social benefits and must be considered as a
viable policy choice (Cameron & Williams, 2001).
A study, consisting of data from the 1990-1996 National Household Survey on
Drug Abuse (NHSDA), developed a measure of the probability of being arrested for
marijuana possession, which consisted of dividing the number of marijuana possession
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arrests for youths aged 12-20 by the number of current young (also aged 12-20)
marijuana consumers. Arrest data were retrieved from the Uniform Crime Reports for the
years 1990-1996. Farrelly et al. demonstrate that a 10% increase in the probability that a
marijuana user is arrested for possession decreases the probability of use by roughly 3%
(Farrelly, Bray, Zarkin, & Wendling, 2001).
A number of law enforcement agencies focus their resources on other illegal
activities, thus giving unscrupulous and resourceful criminals an opportunity to operate
within the illegal drug market without the high costs of arrest, fines, and possible jail time
associated with other criminal activity. When given a choice on supplying the illegal drug
market or illegal firearms market most criminals choose the drug market due to high
transaction costs within the gun market (Cook, Ludwig, Venkatesh, & Braga, 2007). Gun
violence in the U.S. also carries with it tremendous costs on society, estimated to be in
the order of $100 billion per year (Cook & Ludwig, 2000). Regulations exist to prohibit
some members of society from owning and/or possessing a firearm, namely youths and
persons with specific criminal records. For example, the federal felon in possession of a
firearm statute prohibits persons with certain criminal convictions from any court,
including foreign, from possessing firearms (D. K. Taylor, 2004). Due to these
restrictions, illegal firearm markets have been established. However, the illegal firearm
market has lagged dramatically behind the illegal drug market in ease of access,
profitability, and breadth.
Law enforcement activities appear to be more effective in suppressing the supply
in the illegal gun market than in other underground markets, such as illegal drugs,
partially due to the fact that street gangs that are well-positioned to deal in the gun market
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avoid doing so for fear of attracting more serious police attention, thereby jeopardizing
the profits associated with the more lucrative drug trade (Cook et al., 2007). One reason
for this is that the police may view gun possession more seriously than possession of
some illegal narcotics, therefore acting more aggressively in seeking out those who carry
illegal firearms due to the threat of potential violence.

Medical Marijuana
In 2006 the Food and Drug Administration (FDA) issued a statement asserting
that marijuana smoking is not approved for the treatment of any medical condition or
disease (Harris, 2006). Federal drug policy defines marijuana as a Schedule I drug largely
due to the drug’s  well-known  psychoactive  effects,  commonly  referred  to  as  the  “high”  
(Chapkis, 2007). The Institute of Medicine (IOM) has also weighed in on the topic of
using marijuana for medical purposes. In 1999 the IOM issued a  report  titled  “Marijuana  
and Medicine: Assessing the Science  Base.”  The  IOM  stated  that  smoking  marijuana  is  in  
fact a THC delivery system, but also delivers harmful substances, and therefore smoked
marijuana should generally not be recommended for medical use (Joy, Stanley J. Watson,
& John A. Benson, 1999).
This  report,  although  more  than  10  years  old,  still  stands  as  the  “clearest  statement  
of scientific understanding about the  therapeutic  potential  of  marijuana”  ("IOM report
still sets standard on medical marijuana," 2009). The IOM report further stated that the
“future  of  cannabinoid  drugs (substances that are structurally related to
tetrahydrocannabinol or THC, the psychoactive ingredient in marijuana) lies not in
smoked marijuana but in chemically defined drugs that act on the cannabinoid systems
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that are a natural component of human physiology.”  However,  the  United  States  Court  of  
Appeals for the Ninth Circuit in San Francisco heard arguments in April of 2009
concerning  a  lawsuit  originally  filed  in  2007  challenging  the  government’s  skepticism  
about medical uses of marijuana (McKinley, 2009).
Many in the medical community, including physicians, psychiatrists, and
addiction specialists, warn that the medical community should be cautious before
declaring  marijuana  as  “safe”  (Moran, 2009). One study of 42 medical marijuana
patients concluded it was difficult or impossible to separate the medical benefits of
marijuana from its high-generating effect (Chapkis, 2007). In spite of studies such as this,
the number of states passing medical marijuana ordinances has increased. As of March
2009 dispensing marijuana for medical purposes is legal in 13 states (Moran, 2009) and
the number of medical marijuana dispensaries is certain to increase in the coming years.
The American College of Physicians has called for a reclassification of marijuana from a
Schedule I drug (one that is deemed to have high abuse potential and no proven medical
purposes) to a different schedule which would make the drug more readily available to
researchers and clinicians (Moran, 2009). A reclassification could possibly lead to more
concrete studies of the actual effectiveness and efficiency of medical marijuana in
treating many ailments. More scientific research is needed when studying medical
marijuana use because many of the effects of the drug will not show up in an eight-week
trial (Moran, 2009).
The  most  recent  Bush  Administration’s  view  was  that  federal  marijuana  laws  took  
precedent over state law, but now President Obama stated that he would be a supporter of
medical marijuana use, saying in November  2007  that  “there’s  no  difference  between  
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(marijuana)  and  morphine  when  it  comes  to  just  giving  people  relief  from  pain”  
(Alexander, 2009).  Following  President  Obama’s  2009  initiative  to  stop  using  federal  
marijuana laws to override state laws to punish consumers of marijuana for medical
purposes, the requests for information by persons who wish to obtain certifications that
allow individuals to purchase, possess, and consume medical marijuana have increased
up to 300% (Alexander, 2009).
Pro-marijuana groups have also applauded recent remarks by Attorney General
Eric Holder, Jr., who has suggested that federal law enforcement resources would not be
used to pursue legitimate medical marijuana users in states that have laws allowing for
medical use of the drug, but National Organization for the Reform of Marijuana Laws
(NORML) director Allen St. Pierre cautioned that any legal changes would most likely be
only incremental (McKinley, 2009).
Medical marijuana supporters have downplayed the psychoactive effect (the high)
and instead argued for the medical utility and therapeutic potential of marijuana use
(Chapkis, 2007). Supporters point to medical marijuana as a means to sooth and treat
ailments for AIDS patients, offer relief from glaucoma, and reduce nausea in cancer
patients.
However, data retrieved from records seized from medical marijuana dispensaries
in San Diego from October 2005 through July 2006 by the Drug Enforcement Agency
indicated that only 2% of medical marijuana consumers indicated their medical condition
as AIDS, glaucoma, and/or cancer (ONDCP, 2008). The remaining 98% listed their
medical condition as muscle spasms, insomnia, back/neck/post-surgical pain, anxiety,
headache, and other.
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In Colorado, Christian Thurstone M.D., a board certified child/adolescent and
addictions psychiatrist, reviewed all persons who have received medical marijuana
licenses to consume medical marijuana and discovered only 3% have cancer and 1% have
HIV (Thurstone, 2010). Moreover, 90% of Colorado medical marijuana patients received
their  license  with  “pain”  being  the  medical  condition  on  record  (Thurstone, 2010). Dr.
Thurstone also describes an instance when a young, pregnant woman was recommended
(physicians cannot prescribe marijuana but state laws allow for them to recommend its
use) medical marijuana due to nausea.
With few restrictions and regulations on medicinal marijuana the potential for
abuse is high. Medical marijuana dispensaries are attracting youths in greater numbers,
due to the fact that youths are more likely to abuse marijuana. Medical dispensary
customers are relatively young, with four out of five being 40 or younger (ONDCP,
2008).
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CHAPTER II
METHODS

For the scope of this paper, state level data for marijuana consumption during the
years of 1999-2007 will be examined. Data for this paper were gathered from the
National Survey on Drug Use and Health (NSDUH) (smoked marijuana past month and
perception of great risk of smoking marijuana once a month), The Price and Purity of
Illicit Drugs report (marijuana prices), MayaTech Corporation (marijuana penalties), and
ProCon.org (medical marijuana states).
One focus of the NSDUH is to collect data concerning substance prevalence, use,
and abuse. Information is collected regarding alcohol, tobacco, and drug use in
frequencies and quantities ranging from lifetime use, yearly use, monthly use, as well as
date of first exposure. Demographic data is available for the nation as a whole; however,
to ensure anonymity demographic variables are not available at the state level.
Two states (Arizona and Maryland) have not passed laws that allow for the use of
medical marijuana, but have regulations that are favorable toward medical marijuana
usage. In 1996, Arizona voters approved Ballot Proposition 200, which in part allowed
permitted doctors to recommend Schedule I controlled substances, including marijuana,
to treat a disease or to relieve pain and suffering in seriously ill and terminally ill patients
(ProCon.org, 2010). In Maryland, Senate Bill 502 was approved in 2003 which allows
defendants being prosecuted for the use or possession of marijuana to introduce evidence
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of medical necessity and physician approval, which could be considered by the court as a
mitigating factor (ProCon.org, 2010). Neither Arizona nor Maryland was classified as a
medical marijuana state for the purpose of this study.
For purposes of this study, twelve states have also been labeled as
“decriminalized.”  Decriminalization  refers  to  a  reduction  in  state  level  sanctions  for  
possessing small quantities of marijuana. Decriminalization of marijuana on the state
level does not revert marijuana to the status of a legal good, but designates first-offense
marijuana possession as a civil offense rather than a criminal one, resulting in small
monetary sanctions rather than prison sentences (Model, 1993). These states include
Alaska, Arizona, California, Colorado, Maine, Minnesota, Mississippi, Nebraska, New
York, North Carolina, Ohio, and Oregon. These twelve states have commonly been
referred  to  as  “decriminalized”  in  the  drug  policy  debate literature and are commonly
grouped together in empirical analyses (Pacula et al., 2003).

Descriptive Statistics
Table 1 represents state level data of the age groups 12-17, 18-25, and 26 and
older. Variables include past month marijuana consumption (% reporting use), marijuana
risk perception (% reporting great health risk of smoking marijuana once a month),
marijuana price per gram (2007 dollars), residing in a medical marijuana state (0= no, 1=
yes), residing in a decriminalized marijuana state (0= no, 1= yes), marijuana possession
personal use quantities maximum years of imprisonment for first offense (then-year
sentence), marijuana possession criminal classification type for first offense (0= petty
crime, 1= misdemeanor, 3 = felony), and marijuana possession maximum fine for first
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offense personal use quantities (logged then year dollars). Marijuana possession
maximum fine was logged due to the large maximum monetary fine ($150,000) for the
state of Arizona.

Variable
MjSmkPastMonth
(0=no, 1=yes)
MjRiskPerception
(1=no risk, 2=slight
risk, 3=moderate
risk, 4=great risk)
MjPricePerGram
MedMj
(0=no, 1=yes)
DecriminaledState
(0=no, 1=yes)
MjMaxYrsPrison
MjCrimClass
MjMaxFine

Scale

TABLE 1
Descriptive Statistics
All Age Groups 1999-2007
Mean
Std. Dev.

Min

Max

Obs

% reporting

9.360458

6.016256

1.27

32.79

1377

% reporting
2007 dollars

34.03374
10.29553

9.339651
2.517679

10.24
5.17

61.5
16.33

1377
1377

0-1

0.1742919

0.3794982

0

1

1377

0-1
then year
sentence
1-3
nominal
dollars

0.2352941

0.4243366

0

1

1377

0.5900218
1.823529

0.6346043
0.4732047

0
1

4
3

1377
1377

3951.634

20688.13

0

150,000

1377

Consumption Trends and Perceptions of Health Risk
As shown in Table 2, marijuana consumption is highest for the age groups with
the lowest level of risk perception. Mean perception that occasional use (once a month)
of marijuana is a great risk for age group 12-17 was 34.61% with a corresponding past
month consumption rate of 7.79%. For age group 17-25 mean perception that occasional
use of marijuana is a great risk was 24.64% with a corresponding past month
consumption rate of 16.51%, and for those age 26 and older the mean perception that
occasional use of marijuana is a great risk was 42.85% with a corresponding past month
youth consumption rate of 3.78%.
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TABLE 2
Marijuana Consumption Past 30 Days and Perception of Harm by Age Group
1999-2007
Age 12-17
MjSmkPastMonth
MjRiskPerception

Scale
% reporting
% reporting

Mean
7.791895
34.60967

Std. Dev.
1.722631
4.740224

Min
4.39
22.61

Max
Obs
13.9 459
48.03 459

Age 18-25
MjSmkPastMonth
MjRiskPerception

% reporting
% reporting

16.50512
24.63924

4.409597
5.424765

7.44
10.24

32.79
41.28

459
459

Age 26+
MjSmkPastMonth
MjRiskPerception

% reporting
% reporting

3.784357
42.85231

1.244127
6.591783

1.27
26.33

7.99
61.5

459
459

From 1999 through 2007 the percentage of individuals in all age ranges who
consumed marijuana within the past 30 days increased by 11.4%, while the perception of
harm from occasional marijuana consumption decreased 10.79% (Table 3). For the age
group 12-17 the percentage of individuals who consumed marijuana within the past 30
days decreased by 12.68%, with the perception of harm from occasional marijuana
consumption decreasing by 5.74%. For those ages 18-25 past month consumption
increased 18.18% with the perception of harm decreasing 14.60%, and for ages 26 and up
consumption increased 42.40% with perception of harm decreasing by 12.52%. This
suggests that as risk perception decreases consumption increases, especially for those 18
and older.
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TABLE 3
Marijuana Consumption Past 30 Days and Perception of Harm
by Age Group 1999 and 2007
1999 Mean
2007 Mean
Obs
All Ages
MjSmkPastMonth
8.47%
9.44%
153
MjRiskPerception
36.86%
32.88%
153
Age 12-17
MjSmkPastMonth
MjRiskPerception

7.92%
36.52%

6.92%
34.42%

51
51

14.52%
27.24%

17.16%
23.26%

51
51

2.99%
46.82%

4.25%
40.96%

51
51

Age 18-25
MjSmkPastMonth
MjRiskPerception
Age 26+
MjSmkPastMonth
MjRiskPerception

Current Marijuana Smoker
With respect to the dependent variable of current marijuana smoker, marijuana
health risk perception (r = -.884, p < .05) showed the strongest correlations to current
marijuana consumption for all age groups (Table 4). This indicates that consumption of
marijuana increases as the perception of health risks decreases. Price per gram (r = .094,
p < .05) has a weak correlation to past month marijuana consumption suggesting that
consumers are not price sensitive at this level of consumption. Residing in a medical
marijuana state (r = .153, p < .05), decimalized state (r = .05), marijuana possession fines
(r = -.030), criminal classification (r = -.096, p < .05), and maximum years in prison (r =
.024) also are weakly correlated to past month marijuana consumption for all age groups.
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X1
MjSmkPastMonth
MjRiskPerceptionn
MjPricePerGram
MedMj
DecriminalizedState
MjMaxYrsPrison
MjCrimClass
MjMaxFine
AgeRange

TABLE 4
Correlation All Age Groups 1999-2007
X2
X3
X4
X5

1
-0.884*
1
0.0941* -0.1837*
0.1527* -0.2474*
0.0499 -0.0725*
-0.024
0.0352
-0.0961* 0.1259*
-0.0303
0.0247
-0.2720* 0.3604*

X6

X7

1
0.2205*
1
0.0038 0.3409*
1
0.0262 -0.0569* -0.4251*
1
0.1929* -0.0957* -0.3794* 0.543*
1
0.1050* -0.0653* 0.2385* 0.126* 0.3717*
0.00
0.00
0.00
0.00
0.00

X8

X9

1
0.00

1

* p < .05

Changing state level laws that allow for medical marijuana will increase demand,
leading to an initial increase in prices. A weak positive correlation (r = .221, p < .05)
exists between marijuana price per gram and a state that allows for medical marijuana for
all age ranges. This price increase is expected to be short-term, until which time
additional medical marijuana dispensaries are established and opened for business,
leading to increased competition followed by long run price decreases.
Medical marijuana state and the risk perception of harm by consuming marijuana
has a stronger correlation than between price and health perception. This correlation of
medical marijuana state and health risk perception (r = -.247, p < .05) indicates that as
more state laws allow for medical marijuana the perception that marijuana consumption
does  not  pose  a  great  threat  on  one’s  health increases. As states allow for marijuana use
as medication, the perception is not only that marijuana consumption is not harmful, but
it also can actually benefit persons and ameliorate certain conditions. Perceived medical
benefit has led to an increase in consumption, as was the case of alcohol consumption in
Australia which realized an increase in regular drinkers from 1995 to 2001 when
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consuming small amounts of alcohol was professed to have health benefits (Zhao &
Harris, 2004).
Among the three age ranges the strongest negative correlation with past month
marijuana smoking is marijuana health risk perception. The strongest negative correlation
was seen in the 12-17 year olds (r = -.702, p < .05), then the 26 years and older (r = -.755,
p < .05), and the strongest negative correlation was for those 18-25 (r = -.830, p < .05).
The perception of risk of consuming marijuana is correlated negatively with marijuana
use (Hemmelstein, 1995).
Among 12-17 and 18-25 year olds, residing in a medical marijuana state was also
weakly correlated (r = .355, p < .05; and r = .340, p < .05), with past month marijuana
consumption. For those age 26 and up, residing in a medical marijuana state is
moderately correlated with past month marijuana consumption (r = .519, p < .05).
Marijuana health risk perception was also moderately negatively correlated for the age
ranges of 12-17 and 26 and older (r = -.402, p < .05; r = -.490, p< .05) with residing in a
medical marijuana state. Marijuana health risk perception is weakly negatively correlated
for the age range of 18-25 (r = -.332, p < .05). This suggests that the legal acceptance of
medical marijuana negatively influences the perceived health risk of consumption.
Price has the greatest influence on past month marijuana consumption for those
age 26 and older, (r = .406, p < .05), followed by ages 18-25 (r = .256, p < .05). Price has
almost no influence on those 12-17 (r = .038), although this is not statistically significant.
The variables with the weakest correlation among 12-17 year olds with current
marijuana consumption are maximum years in prison (r = .011) and maximum monetary
fine (-.028), although none are statistically significant at the .05 level. For those age 18-
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25 the variables with the weakest correlation are maximum years in prison (r = -.094, p <
.05), maximum monetary fine (r = -.101, p < .05), and decriminalized state (r = .109, p <
.05). For those age 26 and over the variables with the weakest correlation are maximum
years in prison (r = -.033), although not statistically significant, maximum monetary fine
(r = -.042, p < .05), and marijuana possession criminal classification (r = -.123, p < .05).
This indicates that statutory penalties intended to discourage marijuana consumption will
have little effect on marijuana consumption for this age group. Marijuana is also price
inelastic for this age group, resulting in little change in consumption as price increases.

OLS Regression
An ordinary least squares (OLS) regression was performed to measure the
influence multiple variables have on past month marijuana consumption. Residing in a
medical marijuana state (β  =  -1.074) was the strongest single predictor of past month
marijuana use. Marijuana possession criminal classification for  marijuana  possession  (β  =  
.656) was the second strongest influencer, marijuana health risk perception was third
strongest  (β  =  -.590), residing in a marijuana decriminalized state (β  =  .454) is fourth, and
marijuana  price  per  gram  (β  =  -.157) was fifth strongest respectively. Possible maximum
monetary fine for marijuana possession was the weakest influencer on youth marijuana
consumption with almost zero effect.
All variables in the model were significant at a minimum of the .05 level, except
for decriminalized state and marijuana possession maximum years in prison. Examined as
a whole, this model explains 79% (R2 = .7909) of the variance shown in past month
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marijuana consumption for all age groups during the years 1999-2007. Results of the
OLS are displayed in Table 5.
TABLE 5
OLS Regression All Age Groups 1999-2007
Source
Model
Residual
Total

SS
39392.4538
10412.3222
49804.76

df
7
1369
1376

MS
5627.4934
7.60578684
36.1953314

MjSmkPastMnth
MjRiskPerception
MjPricePerGram
MedMj
DecriminalizedState
MjMaxYrsPrison
MjCrimClass
MjMaxFine

Coef.
-0.5901084
-0.1574451
-1.074176
0.4536885
-0.0411901
0.6560762
-9.14E-06

Std. Err.
0.0084139
0.0316834
0.226147
0.2394669
0.1472103
0.2225001
4.43E-06

t
-70.14
-4.97
-4.75
1.89
-0.28
2.95
-2.06

Number of obs = 1377
F (7, 1369) = 739.90
Prob > F = 0.0000
R-squared = 0.7909
Adj R-squared = 0.7899
Root MSE = 2.7580
P> |t|
0.000
0.000
0.000
0.058
0.780
0.003
0.039

[95% Conf. Interval]
-.6066139 -.5736029
-.2195982 -.0952919
-1.517808 -.6305442
-.0160734 .9234504
-.3299723 .2475921
.2195981 1.092554
-.0000178 -4.41e-07

For the age range 12-17, the variables with the greatest influence on past month
marijuana consumption, when holding all other variables constant, are residing in a
medical marijuana state (β  =  .464, p < .05) and marijuana health  risk  perception  (β  =  .267, p < .05). Marijuana possession  maximum  fine  (β  =  .000) demonstrated no influence
on past month marijuana consumption, although not at a statistically significant level. For
the age range 12-17 the OLS model explains 54% (R2 = .5425) of the variance shown in
past month marijuana consumption.
For those age 18-25, marijuana  possession  criminal  classification  (β  =  -1.31, p <
.05),  residing  in  a  medical  marijuana  state  (β  =  .846, p < .05), and marijuana health risk
perception  (β  =  -.616, p < .05), showed the greatest influence on past month marijuana
consumption. The OLS model when examining the age range 18-25 explains 70% (R2 =
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.704) of the variance shown in past month marijuana consumption. The variable with the
weakest influence on past month marijuana consumption is marijuana possession
maximum  fine  (β  =  .000),  although  not  statistically  significant.
The variables with the greatest influence on past month marijuana consumption
for  those  26  and  older  are  residing  in  a  medical  marijuana  state  (β  =  .518, p < .05),
residing in a decriminalized state (β  =  .213, p < .10), and marijuana health risk perception
(β  =  -.114, p < .05). The OLS model when examining this age range explains 62% (R2 =
.623) of the variance shown in past month marijuana consumption. The variable with the
least influence on past month marijuana consumption is marijuana possession maximum
fine  (β  =  .000),  although  not  statistically  significant.
Price was not a significant influence on past month marijuana consumption
among the age ranges of 12-17, 18-25,  and  26  and  older  (β  =  -.147,  β  =  .111,  and  β  =  .083  
respectfully) with all being statistically significant at the .05 level. This contradicts
previous studies that have demonstrated that price has an inverse relationship with
marijuana consumption (Caulkins & Reuter, 1998; Clements & Daryal, 1999; Grossman,
Chaloupka, & Shim, 2002; Pacula et al., 2000), with one study demonstrating that price
plays  a  “significant”  factor  in  marijuana  consumption  (Daryal, 1999).
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CHAPTER III
RESULTS

This study demonstrates the complex nature of health risk behaviors on an
ecological level, and the need for policymakers to account for the numerous variables
involved, rather than focusing on only a single variable, such as price. The influence of
these variables is relevant for gaining a better understanding of health risk behaviors.
Marijuana use has also been demonstrated to result in enormous social costs.
These social costs include a variety of cancers, mental illness, and lost productivity.
Marijuana, the most commonly used illegal drug in the developed world, has generated
tremendous revenues. State and federal governments have only recently began collecting
tax monies.
Perceptions of health risk of marijuana vary from persons age 12-17, 18-25, and
26 years of age and up. Of the three age groups, persons age 26 and older perceive the
health risks to be the greatest for occasional marijuana consumption, trailed by youths
age 12-17, and 18-25 with the lowest perception of health risk. This demonstrates that the
health risk perception of smoking marijuana once a month decreases in adolescence
before increasing after the age of 26. For optimal efficiency, anti-marijuana policies need
to be designed and implemented that focus on increasing the perception of health risk
among this youngest age group. The probability that youths initiate participation in one of
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these health risk behaviors is higher than that of adults due to their lower perception of
health risk (Cohn, Macfarlane, Yanez, & Imai, 1995). This hypothesis is reinforced by
this  study  as  we  have  demonstrated  that  as  an  individual’s  age  increases,  he/she  is  less  
likely to consume marijuana since as one ages their negative health risk perception of
marijuana consumption increases.
Statutory penalties have also been shown to have little success in discouraging
long-term consumption of marijuana. These penalties, both in monetary terms and/or
imprisonment, are inadequate deterrents primarily due to the fact that they remain mostly
unknown by the offenders. This is not to suggest that these penalties be removed, but
rather to suggest that they are included into policies that aim at educating youths on the
risks of using such substances. Enforcement must also be continued due to the fact that if
enforcement is lax or nonexistent the deterrent effect is weakened. Designing policies
that educate end-users to the actual penalties of marijuana use and possession into
messages intended to increase the health risk perception of marijuana consumption may
enhance the goal of youth marijuana cessation.
Youth involvement in the health risk behavior of marijuana consumption can be
reduced simply by raising the level of perceived risk (Cohn et al., 1995). Tobacco
policies have had tremendous success in raising this level of health risk perception in the
past by anchoring tobacco policy firmly in the area of public health rather than the legal
system.
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CHAPTER IV
DISCUSSION
Several of the environmental factors that lead to health risk behaviors have been
identified in this study. Prior to designing and implementing new anti-marijuana
strategies, policy makers must answer one question: Is marijuana consumption a health
risk? If the answer is yes, then the design of anti-marijuana policy must be shifted away
from law enforcement policy and into the field of public health policy. This is not to be
confused with advocating for marijuana legalization and/or decriminalization, but rather a
paradigm shift in the problem of marijuana consumption itself. Law enforcement policy,
which has primarily focused on the supply-side of marijuana, has not been successful in
designing long-term initiatives to reduce youth marijuana consumption. These policy
shortcomings have opened the door for some to question the efficiency of said policies.
In addition to the efficiency debate concerning anti-marijuana policies, initiatives
suggesting legalizing and taxing marijuana have gained momentum as an additional
revenue stream in these trying economic times. During this debate, health outcomes
concerning marijuana use are surprisingly absent. Public health officials must become
involved in the policy process aiding in the design of demand-side policies intended to
reduce  the  prevalence  of  youth  marijuana  consumption.  Law  enforcement’s  role  should  
be concentrated on actively enforcing existing marijuana regulations while these new
public health policies are implemented.
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Current resources directed at supply-side policies (law enforcement and/or
military strategies) designed to increase the overall cost of marijuana should be reduced
and reallocated toward policies that are more cost effective. Prior studies have also
concluded that supply-side initiatives have had little long-term effects on illegal drug
consumption or beneficial public health outcomes (Dobkin & Nicosia, 2008; Wood et al.,
2003). The correlation of current marijuana smoker and price per-gram of marijuana (r =
.094) is weak, and even suggest marijuana is not a normal good.
Demand-side initiatives, such as treatment and education, have been successfully
implemented on the part of public health officials in reducing tobacco use. The single
strongest predictor of ending personal utilization of these goods lies in increasing the
perception of harm caused by consumption. Marijuana consumption is similarly
influenced by health risk perception. A strong correlation exists between current
marijuana consumption and health risk perception (r = -.884).
In addition to direct health risk perception initiatives, steps must be taken to
decrease the number of states allowing marijuana use for medicinal purposes. The
correlation between current marijuana use and medical marijuana state (r= .153) is weak
for all age groups, but is when each age group is examined separately the correlation is
much stronger for those age 12-17 (r= .3552), 18-25 (r= .3401), and 26 and older (r=
.5193). As marijuana for medicinal purposes becomes normalized  youth’s  perception  that  
marijuana is not harmful increases, leading to increased usage. Restrictions, or lack
thereof, reinforce the norms and expected behavior of the individual within their
environment.

35

Demand-side policies that focus on increasing the health risk perception of
marijuana consumption may result in a decrease of youth marijuana use. During the time
period of this study, the majority of marijuana policy funding was designated for
enforcement and not educational purposes. In 2009 $100 million of the $13.7 billion
budget  for  the  White  Houses’  National  Drug  Control  Strategy  was  allocated  for  the  
purpose of educating youth on the harms of illegal drug use. There is not a lack of drug
control policy funds, but rather these funds have largely been misdirected, focusing
primarily on supply-side policies. If marijuana policies mirrored those of anti-tobacco
policies that have successfully increased the health risk perception, then the expectation
would be for marijuana consumption to also decrease.

Future Research
The complex a dataset developed for this study is not without its weaknesses. The
narrow time frame of 1999-2007 presents questions concerning the applicability of any
conclusions drawn from this analysis. Limitations of information contained within more
recent data sources restricted the timeframe available. The real significance of this study
is an enhanced understanding of how these variables as a whole interact and influence
behavior. We have demonstrated that health risk perception of marijuana is the key
variable influencing this health risk behavior. We have also demonstrated that variables
such as criminal sanctions and price, when examined en masse, play a much smaller role
than previous studies have suggested.
Additional data that would have been effective for further analysis in this study
was state level demographic information. Due to the fact that survey participants could
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potentially be identified, through a form of reverse engineering responses, state level data
are not available with regards to certain demographic variables such as race, sex, and
gender. This information may have provided specific state level consumption patterns
based on these demographic variables that the available more general data does not
provide.
Furthermore, this study should not be interpreted as suggesting that no additional
health risk behaviors warrant examination with regard to their association with youth
marijuana consumption. Youths who participate in one form of risky behavior are more
likely to participate in another (Benthin, Slovic, & Severson, 1993). Additional health
risk behaviors that merit future examination include alcohol consumption, unprotected
sex, and other illicit drug use such as ecstasy, cocaine, and heroin, to name but a few.
Alcohol also merits future assessment as to what degree alcohol use among
youths is associated with marijuana consumption due to the high likelihood of abuse and
ease of access. Studies have shown that youths who consume alcohol are more likely than
non-drinkers to have an opportunity to try marijuana (Wagner & Anthony, 2002).
Identifying additional associations between health risk behaviors is vital to
increasing the public health of society, and youths in particular, due to the fact that if one
behavior is reduced or eliminated then the complementary behavior may also be reduced.
Reframing many of these health risk behaviors from the criminal justice spectrum to one
of public health allows health policy makers, advocacy groups, and health organizations
to design and implement educational initiatives that have a higher probability to produce
positive health outcomes.
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Despite these potential shortcomings, the data sources utilized were extremely
comprehensive and allowed us to examine several variables that were strongly associated
with the health risk behaviors of youth marijuana consumption. By examining these
numerous variables a clearer understanding of the environmental influences on health
outcomes were formed, while also allowing us to identify the factors that have not been
successful in altering youth health risk behaviors.
Overall, this study has demonstrated that the single strongest determinant of the
health risk behavior of marijuana consumption is the perception of health risk. By
shifting marijuana policy from the realm of law enforcement and into the domain of
public health, policy makers can increase the probability of creating a successful strategy
that will reduce both the prevalence and incidence of youth marijuana consumption. The
dilemma is not that there is a lack of resources, but rather that these resources are
misdirected. By focusing on creating policies that educate youths on the dangers of
marijuana consumption, health risk perception will increase. This will result in a decrease
in the number of adolescent marijuana smokers, mirroring the positive results that antitobacco policies achieved through public health initiatives.
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